The Impact of Generics on Pharmaceutical Growth Opportunities - A growing threat that offers future opportunities

CBR Pharma Insights, LLC
October 1, 2011
SKU: CBRP3805466
Countries covered: United States

While generic penetration has been on the rise in the major developed markets for some time, the current and continuing difficult economic environment is stimulating political and payer actions to accelerate the trend.

Combined with this, pharma is experiencing a wave of blockbuster patent expiries, with almost $30 billion in US sales (at 2010 levels) exposed by the largest 10 drugs which are expected to experience generic competition for the first time in 2011-2012.

As a result, companies must focus on optimizing their late-stage lifecycle management strategies to maximize at-risk product revenues. But at the same, time generics should be considered not just as a threat but also as an opportunity going forward.

The report, “The Impact of Generics on Pharmaceutical Growth Opportunities”, has been written to support companies with their strategic plans to maximize revenues within the shifting pharmaceutical landscape. The insights, analysis, and support provided can be used by both the branded and generics side of the business.

Key Reasons to Purchase:
  • Compare your company’s lifecycle management strategies with those most appropriate for maximizing generic defense
  • Assess the opportunities available to move into the generics side of the pharmaceutical industry, both in the established and emerging markets
  • Understand the various opportunities that exist to optimize revenue in preparation for your product’s patent expiry
  • Benefit from the analysis of multiple case studies to help support your company’s/brand’s strategy moving forward
  • Learn from the assessments of actual tactics companies have taken, both branded & generic, to drive future revenue growth in this new era of generics



More Manufacturing, Packaging & Detailing reports by CBR Pharma Insights, LLC

Opioids Market Overview to 2023 - Opioids in Emerging Markets by CBR Pharma Insights, LLC
Opioids Market Overview to 2023 - Opioids in Emerging Markets Summary The report provides analysis of new developments that will have a strong ...
Opioids Market Overview to 2023 - Opioids in Western Europe by CBR Pharma Insights, LLC
Opioids Market Overview to 2023 - Opioids in Western Europe Summary The report provides an estimation of 2013 opioid revenues and forecast consumption ...
Biosimilars - Biosimilars on the cusp of a new era by CBR Pharma Insights, LLC
Biosimilars - Biosimilars on the cusp of a new era The biosimilars market is undergoing rapid change with developments such as the recent approvals of ...
Pediatric Drug Development - Regulatory challenges and commercial opportunities by CBR Pharma Insights, LLC
Pediatric Drug Development - Regulatory challenges and commercial opportunities Although pediatrics represent around two-fifths of the global population the market for pediatric medicines remains relatively ...
See all reports like this >>

More United States Manufacturing, Packaging & Detailing reports

U.S. Life Science 2015 Top 10 Predictions by IDC
U.S. Life Science 2015 Top 10 PredictionsThis IDC Health Insights report identifies several major trends that we believe will impact life science companies in 2015."Technology ...
Biotechnology Product Manufacturing by First Research, Inc.
Biotechnology Product ManufacturingBrief Excerpt from Industry Overview Chapter:Companies in this industry manufacture drugs, therapies, vaccines, genetically modified food and fuel, and other products based on ...
Pharmaceuticals in USA: ISIC 2423 by Euromonitor International
Pharmaceuticals in USA: ISIC 2423Euromonitor International's Industrial reports provide a 360 degree view of an industry. The Industrial market report offers a comprehensive guide to ...
The US Chronic Pain Market – Focus on Opioids: Trends & Opportunities (2014-19) by Daedal Research
The US Chronic Pain Market – Focus on Opioids: Trends & Opportunities (2014-19) Scope of the Report The report titled “The US Chronic Pain ...
See all reports like this >>

More United States reports

The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United States by Icon Group International, Inc.
The 2013-2018 Outlook for Collagen and (hyaluronic Acid) HA-Based Biomaterials in the United StatesThis econometric study covers the latent demand outlook for collagen and (hyaluronic ...
The 2013-2018 Outlook for Relish in the United States by Icon Group International, Inc.
This econometric study covers the latent demand outlook for relish across the states and cities of the United States. Latent demand (in millions of U.S. ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 3,900  
    Global Site License  USD 9,800  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!